Vivos Therapeutics financials
$0.1505+12.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.1M | $3.8M | $6.8M | $3.8M | $3.0M | $3.7M | $3.9M | $4.1M | $3.4M | $3.2M | $3.3M |
| Gross profit | $3.0M | $3.1M | $3.0M | $3.9M | $2.1M | $1.5M | $2.1M | $2.3M | $2.7M | $1.9M | $2.1M | $1.7M |
| Gross margin | 57.3% | 59.5% | 78.1% | 58.0% | 55.2% | 50.0% | 56.7% | 60.5% | 65.4% | 56.7% | 64.3% | 52.9% |
| Operating income | -$4.8M | -$6.6M | -$6.4M | -$4.7M | -$4.9M | -$3.9M | -$2.8M | -$2.6M | -$1.9M | -$3.8M | -$4.1M | -$3.6M |
| Net income | -$5.5M | -$7.7M | -$6.9M | -$5.4M | -$5.0M | -$3.9M | -$2.8M | -$2.6M | -$1.9M | -$3.8M | -$4.3M | -$2.1M |
| Net margin | −106.4% | −149.4% | −180.3% | −79.6% | −131.2% | −128.1% | −76.4% | −67.8% | −47.6% | −110.1% | −131.1% | −63.4% |
| Diluted EPS | $-0.31 | $-0.52 | $-0.55 | $-0.49 | $-0.55 | $-0.45 | $-0.36 | $-0.40 | $-0.60 | $-1.63 | $-2.85 | $-1.75 |
| EBITDA | -$4.3M | -$6.2M | -$5.9M | -$4.3M | -$4.6M | -$3.7M | -$2.7M | -$2.5M | -$1.8M | -$3.6M | -$4.0M | -$3.5M |
| Operating cash flow | -$3.1M | -$6.0M | -$3.8M | -$4.2M | -$3.5M | -$3.8M | -$2.9M | -$4.2M | -$3.0M | -$2.5M | -$2.7M | -$2.8M |
| Free cash flow | -$3.6M | -$6.0M | -$5.3M | -$4.2M | -$4.3M | -$3.9M | -$3.1M | -$4.4M | -$3.1M | -$2.7M | -$2.9M | -$3.0M |
| Diluted shares | 17.7M | 14.6M | 12.4M | 11.0M | 9.1M | 8.6M | 7.9M | 6.6M | 3.2M | 2.3M | 1.5M | 1.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.8M | $2.1M | $2.0M | $3.1M | $4.4M | $2.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $8.3M | $7.9M | $9.0M | $8.9M | $8.1M | $0.00 |
| Total assets | $24.1M | $25.0M | $25.2M | $25.6M | $26.0M | $11.3M |
| Total liabilities | $28.1M | $26.3M | $26.7M | $23.1M | $21.4M | $6.9M |
| Shareholders' equity | -$4.0M | -$1.3M | -$1.6M | $2.5M | $4.6M | $4.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology